Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

Meet Aikido Pharma Inc’s Board of Directors

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

Artificial Intelligence Is Optimizing Drug Development

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

New Board Member Brings Expertise in Oncology Research

Currently in Human Phase 2 Trials for Treatment of Prostate Cancer